Preladenant is an adenosine 2A receptor antagonist that reduced "off" time in a placebo-controlled phase 2b trial in patients with Parkinson disease (PD). We sought to confirm its efficacy in phase 3 trials.
Istradefylline demonstrated efficacy in phase 2 trials, but results in phase 3 trials were inconsistent. [9] [10] [11] [12] [13] [14] Nonetheless, after a successful phase 3 trial in Japan, istradefylline was approved in that country, 12, 14 and an international phase 3 trial is now ongoing (clinicaltrials.gov identifier NCT01968031). Preladenant is a potent and selective A 2A antagonist. 15 In rodent and primate models of PD, preladenant improved motor function. 15, 16 In a phase 2b trial evaluating preladenant as an adjunct to levodopa in patients with PD, 17 a dose response was demonstrated with preladenant (5 mg and 10 mg twice daily) providing a significant reduction in "off" time (time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness) compared with placebo, and preladenant was well tolerated. We report herein results from 2 phase 3 trials that evaluated preladenant as an adjunct to levodopa in patients with PD and motor fluctuations.
Methods

Overview
We conducted two 12-week, phase 3, randomized, placebocontrolled, double-blind trials in patients with PD and motor fluctuations. These trials were identical in design except for treatment arms. In trial 1, patients were randomized to the addition of preladenant (2 mg, 5 mg, or 10 mg twice daily), placebo, or rasagiline mesylate active control (1 mg/d). In trial 2, patients were randomized to the addition of preladenant (2 mg or 5 mg twice daily) or placebo. The study protocols can be found in Supplement 1 and Supplement 2. Trial 1 was conducted at 121 sites in Eastern Europe, the European Union, India, Latin America, North America, and Turkey from July 15, 2010 , to December 20, 2012. Trial 2 was conducted at 88 sites in Eastern Europe, Latin America, North America, and South Africa from March 14, 2011 , to April 16, 2013 . The trials were conducted in accord with principles of good clinical practice and were approved by appropriate institutional review boards and regulatory agencies. Written informed consent was obtained from each patient before participation.
Patients were randomized to treatment ( Figure 1 ) using a computer-generated allocation schedule prepared by Merck & Co, Inc and implemented through an interactive voice response system. Investigators, site staff, patients, and monitoring staff remained masked to treatment allocation throughout the trials.
Patients
Both trials enrolled patients with moderate to severe PD who were experiencing motor fluctuations. Key 
Statistical Analysis
The primary hypothesis in each trial was that at least 1 dosage of preladenant is superior to placebo as measured by change from baseline to week 12 in mean off time. The primary efficacy end point was analyzed using a constrained longitudinal data analysis approach with treatment, time, and treatment × time interaction as fixed effects and with patient as a random effect. The leastsquares mean response and pairwise differences between preladenant dosages and placebo, along with 95% CIs, are reported. Using the same model, a comparison of rasagiline vs placebo was performed in trial 1. The efficacy population (full analysis set) consisted of all randomized patients with baseline data and postrandomization end point data after at least 1 dose of study medication. Key secondary measures were the proportion of responders (≥30% reduction in mean off time from baseline to week 12) and change from baseline in mean on time without troublesome dyskinesia. Other secondary end points were analyzed but were uninformative and are not reported herein except for UPDRS part 3 scores.
Multiplicity was controlled through prespecified sequential testing procedures (eMethods in Supplement 3), whereby starting with the primary end point, the highest preladenant dosage was tested against placebo. If significant (P ≤ .05), the next pre-
Power
For each trial, the planned sample size was 150 patients per treatment group. This number provided at least 90% power to detect a difference between preladenant and placebo of 1 hour in change from baseline to week 12 in mean off time given an SD of 2.6 hours (as observed in the phase 2b study 17 ) and a 2-sided α = .05.
Post Hoc Investigations (Trial 1 Only)
Once results of the studies were known, several post hoc investigations were undertaken. These post hoc analyses focused on trial 1 given that this trial included an active control arm (rasagiline) that failed to demonstrate efficacy. Investigations included an analysis of the integrity of the randomization process and treatment administration. In addition, a pharmacokinetic analysis evaluated whether expected plasma levels for randomized medications were achieved. The potential effect of caffeine consumption at baseline was evaluated by adding a caffeine term to the PRL indicates preladenant; PBO, placebo; and RAS, rasagiline. a Fewer than the number treated because patients with no post baseline data were excluded from the efficacy analyses.
Results
Patients
In trial 1, a total of 778 eligible patients were randomized to the addition of preladenant (2 mg, 5 mg, or 10 mg twice daily), placebo, or rasagiline mesylate (1 mg/d) in a 1:1:1:1:1 ratio. The full analysis set included 769 patients, and 106 discontinued treatment ( Figure 1A ). In trial 2, a total of 476 eligible patients were randomized to the addition of preladenant (2 mg or 5 mg twice daily) or placebo in a 1:1:1 ratio. The full analysis set included 473 patients, and 50 discontinued treatment ( Figure 1B) . In both studies, discontinuations were similar across treatment groups.
Patient characteristics are summarized in Table 1 . Baseline demographics were broadly similar between the 2 trials in terms of patient age and PD history. Treatment groups were similar in baseline disease severity.
Efficacy
In trial 1, neither preladenant nor rasagiline was superior to placebo in reducing off time from baseline to week 12 (eFigure 1A in Supplement 3). The differences vs placebo were −0.10 hour (95% CI, −0.69 to 0.46 hour) for preladenant 2 mg twice daily, −0.20 hour (95% CI, −0.75 to 0.41 hour) for preladenant 5 mg e Based on the full analysis set (see study flowcharts for sample sizes).
twice daily, −0.00 hour (95% CI, −0.62 to 0.53 hour) for preladenant 10 mg twice daily, and −0.30 hour (95% CI, −0.90 to 0.26 hour) for rasagiline mesylate 1 mg/d ( Table 2 ). The percentage of responders with at least 30% decrease in off time at week 12 was similar among the preladenant, placebo, and rasagiline groups and ranged from 31.0% to 36.1%. Both the odds ratios and the proportions of responders showed no significant differences between preladenant or rasagiline vs placebo. All preladenant groups and the rasagiline group had numerically larger increases in on time without troublesome dyskinesia than the placebo group; however, none of the preladenant or rasagiline vs placebo differences were significant, nor was there a dose response. In general, changes in UPDRS part 3 scores were similar among treatments, with no significant differences from placebo other than for rasagiline at week 12 (eFigure 2A in Supplement 3).
In trial 2, preladenant was not superior to placebo in reducing off time from baseline to week 12 (eFigure 1B in Supplement 3). The differences vs placebo were −0.20 hour (95% CI, −0.72 to 0.35 hour) for preladenant 2 mg twice daily and −0.30 hour (95% CI, −0.86 to 0.21 hour) for preladenant 5 mg twice daily (Table 2 ). Mean increases in on time without troublesome dyskinesia at week 12 were similar (0.6, 0.7, and 0.5 hour) among treatment groups, and there were approximately 37% responders in the preladenant groups compared with 30.5% for the placebo group. Baseline UPDRS part 3 scores were similar across treatment groups and ranged from 26.2 to 27.7 points. In general, changes from baseline were similar among treatments, with no significant differences from placebo other than for preladenant 5 mg twice daily at week 12 (eFigure 2B in Supplement 3). One death was reported, a suicide (self-inflicted gunshot wound to the chest) in the preladenant 2 mg twice daily group, which was considered possibly related to the study drug by the investigator. The most common adverse event that showed an increase for preladenant over placebo was constipation (8.0% 
Post Hoc Analyses (Trial 1 Only)
Investigations determined that the randomization code and treatments were correctly administered. Treatment groups in trial 1 were generally comparable in terms of demographics, baseline disease characteristics, and concomitant medications (including caffeine use). Review of demographic data and baseline disease characteristics did not reveal any notable differences between the phase 2b trial 17 and the phase 3 trial or differences vs other similar published PD trials 24, 25 (eTable 2 in Supplement 3). Plasma concentrations of preladenant in trial 1 were largely consistent with those in the phase 2b trial (eTable 3 in Supplement 3). The observed mean steady-state rasagiline level in trial 1 was 2.4 ng/mL at 2 hours after dosing, similar to previous trials. 26 Baseline caffeine use was not associated with off time change from baseline (P = .40 for <1 vs ≥1 cup per day and P = .54 for ≤1 vs >1 cup per day). Analyses of potential regional differences (Table 3) found that Turkey, India, and Latin America had the largest mean reductions in off time in the placebo group (range, −1.00 hour to −2.15 hours), leading to numerically greater reductions in off time in the placebo group than in the preladenant or rasagiline groups. The mean placebo group reductions in off time were smaller in North America, the European Union, and Eastern Europe (range, −0.45 to −0.76 hour), leading to treatment responses that were directionally consistent with expectations that rasagiline and preladenant would show benefit vs placebo. However, improvements were still modest, with reductions from −0.39 hour to −1.18 hour in off time for preladenant 5 mg twice daily vs placebo and reductions from −0.57 hour to −0.71 hour in off time for rasagiline 1 mg/d vs placebo. There was no evidence of a dose response in the preladenant groups in any region.
Analyses by enrollment found that the first 50% of patients to be enrolled in trial 1 took approximately 18 months to enroll, whereas the second 50% took only approximately 9 months. Notably, patients in the placebo arm enrolled in the first half had a small response (reduction of −0.03 hour in off time) compared with patients enrolled in the second half (reduction of −1.40 hour in off time) (Figure 2) . In addition, reductions in off time in the preladenant and rasagiline arms were slightly larger in the first half. Overall, patients randomized to preladenant (5 mg or 10 mg twice daily) or rasagiline enrolled in the first half demonstrated significant improvement vs placebo in reduction in off time (approximately 1 hour or more) (eTable 4 in Supplement 3). 
Discussion
In these phase 3 trials, preladenant did not significantly reduce off time compared with placebo. However, because the active control (rasagiline) also failed to demonstrate a significant reduction in off time, it is not possible to determine from these results whether they represent a finding of inefficacy for preladenant or are related to issues of study design or conduct. All 3 A 2A antagonists (istradefylline, preladenant, and tozadenant) have yielded positive results in reducing off time in phase 2 trials (eTable 5 in Supplement 3). [8] [9] [10] 17 However, istradefylline had mixed phase 3 results, 11-14 and our 2 preladenant trials failed (while tozadenant has not yet completed a phase 3 trial). We also note that the designs of the phase 3 trials have been essentially the same as those of the phase 2 trials, which suggests that A 2A antagonists may have efficacy as adjuncts to levodopa but that problems with the execution of the phase 3 trials have hindered our ability to demonstrate this efficacy. Demonstrating reduction in off time by diaries requires enrolling patients who actually have motor fluctuations, who can accurately recognize the various PD motor states (on, off, and dyskinesia), and who will accurately record those states over time in their diaries. Therefore, the investigator must select patients who actually have PD, confirm that the patient has true motor fluctuations, teach the patient to recognize the PD motor states, and verify that the patient understands them. It is then up to the patient to complete the diary in a timely and accurate manner. It seems likely that these requirements would be easiest to accomplish at a small number of expert sites with a successful clinical trial track record and a large population of well-known patients from which to draw, which appears to be the case for phase 2 trials but becomes more difficult in phase 3 trials, when more sites and more participants are required. In fact, the negative phase 3 studies enrolled the most patients (eTable 5 in Supplement 3).
In our post hoc analyses of trial 1, we identified a large placebo effect in Turkey, India, and Latin America, with numerically greater reductions in off time in these regions in the placebo group than in the preladenant or rasagiline groups. The exact reason for this finding is not known, but a large placebo response was also observed in a phase 3 monotherapy trial of preladenant in Latin America, India, Turkey, and Eastern Europe compared with North America and the European Union. 27 We are also aware of a phase 2 trial of fipamezole as an antidyskinetic agent in which benefit was demonstrated in the United States but not in India. 28 The differences could potentially be owing to clinical trial experience, cultural or language variations, genetic variation, or as yet unidentified reasons. Because no stratification or block randomization was used, our subgroup analyses may be subject to bias because they do not represent a fully randomized sample. A subtype analysis was not performed, and subtype response variance may also have affected results. We found that there was a striking difference in results between the first 50% of patients enrolled and the second 50% of patients enrolled in trial 1, the only trial to evaluate this. In fact, if just the first 50% of patients were considered, there was a significant reduction in off time in the preladenant and rasagiline groups compared with the placebo group. Analyses did not suggest that this effect was because of site or regional influences. We hypothesize that the most likely explanation for this finding is that sites enrolled their most ideal patients first. After that, less ideal patients may have been enrolled to satisfy enrollment targets. That the second 50% was enrolled in half the time it took to enroll the first 50% raises concern that an enrollment push by the sponsor or clinical research organization could potentially have degraded the quality of patients that sites were enrolling. These observations are consistent with results of an analysis of 4 phase 3 trials of paroxetine in major depression that found that a significant treatment effect was observed before approximately 100 patients had been enrolled per treatment arm. 29 However, continuing to enroll additional patients (up to approximately 150) did not maintain the achieved level of significance and in one case turned a potentially positive study into a negative study. Notably, pooled analysis indicated that patients in the fourth quarter of enrollment were more likely to be placebo responders than early-enrolling patients. Inclusion of an active control arm was useful to identify trial 1 as a failed trial. Rasagiline has several positive qualities as an active control. Although mild in efficacy and typically well tolerated, it has consistently reduced off time in adjunctive trials. However, exclusion of monoamine oxidase type B inhibitors in our phase 3 trials may have placed an additional burden on enrollment and made it harder for investigators to enroll ideal patients.
To adequately evaluate adjunctive PD medications, investigators must enroll appropriate patients and ensure rigorous diary education. Improved documentation of on and off states may be helpful, including UPDRS motor scoring during the patient's routine on and off states, with a certain amplitude of change required. Although burdensome, central review of diagnosis and confirmation of fluctuations might be considered. Paper diaries are potentially subject to reduced compliance, recall bias, and diary fatigue, and elec-
Box. Lessons Learned
Some Regions May Have Large Placebo Effects
In our trial 1, we observed a large placebo effect in Turkey, India, and Latin America. In a phase 3 preladenant monotherapy trial, 27 a large placebo effect was observed in Latin America, India, Turkey, and Eastern Europe. The reasons for this are not clear. Careful choice of sites and regions may help reduce placebo effects. Treatment stratification by region should be considered for smaller trials to assure balanced assignment of arms. Specialized training to mitigate placebo response is recommended for all sites.
More Patients Is Not Always Better
In our trial 1, post hoc analysis found that if only the first 50% of enrolled patients were considered, both preladenant and rasagiline mesylate significantly reduced off time compared with placebo. Similar observations were made for paroxetine trials. 29 We hypothesize that sites enroll their most ideal patients first and then may "scrape the bottom of the barrel" to find additional patients to enroll. These patients may exhibit a larger placebo effect and may be less ideal in other ways, such as having less distinct motor fluctuations or more difficulty self-identifying their PD motor states. To mitigate this problem, one should avoid having to enroll more patients than are necessary (do not overpower the study and do not unnecessarily include dosage arms thought to be ineffective), consider more sites enrolling fewer patients if more competent sites are available, and avoid pressuring sites to enroll more patients or to enroll patients at a quicker pace.
Pressuring Sites to Increase Enrollment May Have Undesirable Consequences
Pressuring sites to enroll more patients or to enroll patients at a quicker pace may cause them to loosen their standards and enroll less ideal patients (as described above). In our trial 1, the second 50% of participants were enrolled in half the time it took to enroll the first 50%, suggesting that there may have been increased pressure to enroll during the second half of the study.
Avoid Unnecessary Exclusions
Unnecessary exclusions make enrollment more difficult, reduce the pool of eligible patients, and may increase the pressure on sites to enroll less ideal patients. This problem was not specifically identified in our studies but is commonly seen in clinical trials.
Active Control Arms Have Pros and Cons
Inclusion of an active control arm can be useful to confirm a trial's ability to detect efficacy using a medication known to be effective. In our trial 1, that the active control rasagiline did not exhibit efficacy compared with placebo suggested that there were problems with the design or conduct of the trial. This can be useful information to help interpret negative results regarding the active medication. On the other hand, because rasagiline was used as an active control, monoamine oxidase type B inhibitors were exclusionary, and this may have reduced the potential pool of eligible patients and placed an increased enrollment burden on the sites, leading to enrollment of less than ideal participants.
Understand Methodological Weaknesses and Institute Countermeasures Beforehand
In contemporary PD fluctuator trials, there are several responsibilities that are granted to the investigator and the patient such that trial data are dependent on the rigor with which the investigator and patient fulfill these responsibilities. First, the investigator is tasked with enrolling patients with a diagnosis of PD. This item could be strengthened by requiring the investigator or designate to complete a diagnosis criteria checklist that could be reviewed centrally. Second, eligible patients are required to have motor fluctuations, but there are often no clear criteria set. We suggest that UPDRS motor scores should be obtained in the clinic in the patient's usual on and off states, with a change criterion to be met to confirm the presence of motor fluctuations. Videotaped central ratings of on and off UPDRS motor scores would be even more rigorous but are more costly and time-consuming. Third, concordance diary testing to evaluate whether the patient understands the PD diary terminology and can self-identify his or her PD motor states is critically important. Unfortunately, this procedure is often conducted in an informal manner, with ongoing discussion between the rater and the patient. Strengthening this procedure by emphasizing that it is a test and that patient training should be completed before formal concordance testing is undertaken, with no discussion between the rater and patient regarding motor states during testing, should be emphasized. Fourth, receiving reliable data is dependent on the patient completely and accurately completing the diary in a timely fashion. A telephone call to the patient the day before the diary is completed to remind him or her to complete the diary and to review good practice completion instructions may be helpful. Sites should also exercise discretion and not enroll patients who are likely to be poorly compliant in diary completion. Electronic diaries may be helpful to remind patients to complete entries on time and limit entries to 1 per period.
